Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker for evaluating responsiveness and prognosis survival of advanced bladder cancer anti-tumor immunotherapy and application of marker

An anti-tumor immune and reactive technology, applied in the determination/examination of microorganisms, biochemical equipment and methods, etc., can solve unreported problems, achieve less pain for patients, improve sensitivity and accuracy, and reduce treatment costs. Effect

Active Publication Date: 2021-03-12
SHANGHAI FIRST PEOPLES HOSPITAL
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report about a marker of the present invention for evaluating the responsiveness and prognostic survival of advanced bladder cancer anti-tumor immunotherapy and its application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for evaluating responsiveness and prognosis survival of advanced bladder cancer anti-tumor immunotherapy and application of marker
  • Marker for evaluating responsiveness and prognosis survival of advanced bladder cancer anti-tumor immunotherapy and application of marker
  • Marker for evaluating responsiveness and prognosis survival of advanced bladder cancer anti-tumor immunotherapy and application of marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Model Construction and Effect Verification

[0028] 1. Subjects

[0029] The research subjects in this example were selected from patients with advanced bladder cancer who received anti-PD-1 / PD-L1 therapy in the IMvigor 210 trial. The clinicopathological data and gene expression processing data of these patients came from a development data resource based on the R environment—— IMvigor210CoreBiologies. The inclusion and exclusion criteria of patients are as follows:

[0030] (1) Patients with advanced bladder cancer who are ineffective to platinum-based chemotherapy and receive tumor immunotherapy;

[0031] (2) Complete curative effect information and clinical follow-up data;

[0032] (3) have whole-transcriptome RNA sequencing data;

[0033] (4) Patients with unknown tumor immunotherapy results or incomplete survival data were excluded.

[0034] 2. Experimental process

[0035] A total of 298 patients who met the above criteria were included in the stud...

Embodiment 2

[0044] Embodiment 2 kit (1)

[0045] Including detection reagents and instructions, the detection reagents are composed of reagents for detecting the expression of the following six genes: CDH18, CXCL10, FOXN4, SLC6A4, CXCL9 and PCDH11X;

[0046] The instruction manual records the following:

[0047] Nomogram score = 316.215877454-(4.073676019×CDH18)-(7.692307692×CXCL10)-(5.176616243×FOXN4)-(2.733887894×SLC6A4)-(2.520670945×CXCL9)-(3.8812067)PC;

[0048] If the Nomogram score is less than 183, it means predicting immunotherapy response and prognosis survival is a low-risk group, and its 3-year survival rate is 45.1%-52.0%; if the Nomogram score is greater than 183, it means predicting immunotherapy responsiveness The prognosis and survival are high-risk group, and its 3-year survival rate is 20.0%-29.8%.

Embodiment 3-8

[0049] Embodiment 3-8 kit (two-seven)

[0050] Kit 2 Kit 3 Kit 4 Kit 5 Kit 6 Kit 7 Reagents for detection of CDH18 expression √ Reagents for detecting the expression of CXCL10 √ Reagents for detecting the expression of FOXN4 √ Reagents for detecting the expression level of SLC6A4 √ Reagents for detecting expression of CXCL9 √ Reagents for detecting the expression level of PCDH11X √

[0051] All the above kits also include instructions, and the instructions record the following content: when the gene expression level is higher than the normal value of a single gene expression level, it belongs to the low-risk group, and the treatment response is good.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a marker for evaluating anti-tumor immunotherapy responsiveness and prognosis survival of advanced bladder cancer and application of the marker. The marker consists of the following six genes: CDH18, CXCL10, FOXN4, SLC6A4, CXCL9 and PCDH11X. The invention further comprises application of a reagent for detecting the expression quantity of the marker in preparation of a kitfor evaluating responsiveness and prognosis survival of advanced bladder cancer anti-tumor immunotherapy. According to the invention, full transcriptome sequencing is carried out on advanced bladder cancer specimens based on large-sample anti-tumor immunotherapy, and screening and construction are carried out after machine learning, so that the reactivity of the advanced bladder cancer patients receiving the anti-tumor immunotherapy can be efficiently and accurately predicted; effective guidance opinions can be provided for clinicians to make treatment decisions on patients with advanced bladder cancer, invalid treatment is reduced, and therefore the treatment cost and discomfort experience of the patients are reduced.

Description

technical field [0001] The present invention relates to the technical field of prognosis of anti-tumor immunotherapy for patients with advanced bladder cancer, in particular, a marker for evaluating the responsiveness and prognosis of advanced bladder cancer anti-tumor immunotherapy and its application. Background technique [0002] Bladder cancer is one of the most aggressive malignancies in the male population. An estimated 81,400 new cases of bladder cancer and 17,980 bladder cancer-related deaths are expected to occur in the United States in 2020. About 10%-15% of initially diagnosed bladder cancer patients are accompanied by tumor metastasis, and the 5-year survival rate is only 5%. Currently, cisplatin-based combination chemotherapy is the standard first-line treatment for patients with metastatic urothelial carcinoma. However, more than 60% of patients with metastatic bladder cancer are not suitable for continuing to receive cisplatin-based chemotherapy due to poor ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/158
Inventor 陈思腾郑军华王翔胡姗姗张宁张恩承
Owner SHANGHAI FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com